iLoF operates an AI and photonics platform that collects large-scale biological data to create digital twins and a digital library of biomarkers and disease subtypes. The platform is intended to enable biotech and pharmaceutical companies to make clinical trials faster, cheaper, and more patient-centric. The company says different patient profiles can be selected and screened to speed development of personalised treatments and support humane clinical trials. iLoF is fast-tracking ongoing engagements and pilots with global corporations in the pharmaceutical, biotech, and clinical space. Founders Mehak Mumtaz and Luis Valente plan to evolve the platform from a next-generation bioinformatics tool toward a disease screening product to directly help patients. Financially, iLoF raised a $4.1M seed round and a $900k ERDF grant and has $8M in total funding to date. iLoF has developed a disruptive, patented platform that detects nanoscale biomolecules in blood to generate optical ‘fingerprints’ of a patient’s phenotype and disease stage. The cloud-based library aggregates individual nano-sized biomarkers and patient biological profiles correlated with heterogeneous diseases to aid screening and clinical trial matching. The agnostic, label-free technology aims to identify suitable patients for trials, speed drug discovery, and reduce cost and time for pharmaceutical and biotechnology partners. The startup has applied the platform to gastric cancer cell detection and is adapting it to forecast clinical evolution in COVID-19 patients in hospital care. Currently engaged with leading biotechs, pharmas and hospitals, iLoF positions its tools to enable more personalized, non-invasive treatment stratification. Financially, iLoF recently secured additional funding and previously raised support from EIT Health as it scales collaborations and library development.

Total raised

$6M

Funding rounds

3

Latest round

Seed

Latest activity

Jul 2022